TAIPEI (TVBS News) — Taiwan's premier research institution Academia Sinica (中研院) unveiled groundbreaking findings Wednesday (Aug. 20) from the "Taiwan Cancer Moonshot Project" (台灣癌症登月計畫), marking its first comprehensive genomic study of lung adenocarcinoma. The international collaboration with the Clinical Proteomic Tumor Analysis Consortium examined hundreds of cases spanning Europe, America, and Asia, revealing critical disease mechanisms and identifying a dangerous "late-stage-like" subtype in early-stage cancers.
Project leader Yu-Ju Chen (陳玉如) highlighted the study's transformative potential for revolutionizing early detection and precision treatment approaches for lung adenocarcinoma. Chen noted the research uncovered multiple drug targets with significant clinical potential, creating new pathways for early intervention and treatment strategies, with findings published in the prestigious journal Cancer Cell. The research team identified mutation signatures from environmental carcinogens, including polycyclic aromatic hydrocarbons and nitrosamines, as widespread patterns among smoking-related lung adenocarcinoma cases globally.
The research systematically categorized tumors into distinct subgroups linked to common carcinogens, emphasizing the global importance of environmental factors in lung adenocarcinoma development worldwide. Chen detailed how proteomic analysis revealed three major cancer subtypes, with the particularly concerning C2 "late-stage-like" subtype exhibiting molecular patterns resembling advanced tumors despite appearing in early-stage disease. This discovery represents a crucial breakthrough in understanding cancer progression mechanisms.
Chen identified significant gender-specific influences in cancer development, observing that male patients typically encounter external carcinogens like smoking and pollution exposure, while female patients show greater susceptibility to internal carcinogenic factors. The researcher emphasized that future therapeutic approaches could be personalized according to gender differences and specific carcinogenic pathways. The groundbreaking study established new treatment directions by targeting proteins and phosphorylation sites with elevated expression in particular subtypes, creating a comprehensive blueprint for diverse therapeutic strategies.
